Promise Pharmacy Recalls Ipamorelin Injection Due to Sterility Concerns
Promise Pharmacy is recalling 927 vials of Ipamorelin+Modified GRF 1-29 injection because of a lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric for significant injury or property damage reports, or high-risk contamination.
Plain-English summary
Promise Pharmacy, LLC is recalling 927 vials of Ipamorelin+Modified GRF 1-29, 9 mg/5mg injection. The product was distributed nationwide in the USA. The recall was initiated due to a lack of sterility assurance.
The affected lots are 07052018@1, 09182018@6, 09212018@10, 10052018@1, and 11062018@2. The expiration dates for these lots range from January 1, 2019, to April 19, 2019.
Consumers should stop using the product and contact their healthcare provider or the pharmacy for further instructions.
The recalled product
- Product
- Ipamorelin+Modified GRF 1-29, 9 mg/5mg injection, Rx Only, Promise Pharmacy Compounding Specialists 31818 US Hwy 19N, Palm Harbor, FL 34684
- Manufacturer
- Promise Pharmacy, LLC
- Hazard
- Affected units
- 927
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lots: 07052018@1 BUD: 1/1/2019
- 09182018@6 BUD: 3/1/2019
- 09212018@10 BUD: 3/4/2019
- 10052018@1 BUD: 3/18/2019
- 11062018@2 BUD: 4/19/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 51 recalled by Promise Pharmacy, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 51 products in this recall →Related recalls
Same manufacturer · Promise Pharmacy, LLC
See all →- SevereMIC+Methyl B12 Injection Recalled for Lack of Processing Controls
FDA (Drugs) · 2021-09-22
- SeverePromise Pharmacy Recalls Lysine HCl Injection Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
- SeverePromise Pharmacy Recalls Acetylcysteine Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
- SeverePromise Pharmacy Recalls Sermorelin Injections Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
- SeverePromise Pharmacy Recalls Epithalon Injections Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SeverePharmcore Recalls Ipamorelin Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2018-09-05
- SevereFDA Recalls Ipamorelin Acetate Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereAssurance Infusion Recalls Ipamorelin Injections Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SeverePharm D Solutions Recalls Sermorelin/Ipamorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereMIC+Methyl B12 Injection Recalled for Lack of Processing Controls
FDA (Drugs) · 2021-09-22
- SeverePharm D Solutions Recalls Sermorelin/Ipamorelin Powder Due to Sterility Concerns
FDA (Drugs) · 2018-11-07